OA10133A - Inhibition of retrovirus infection - Google Patents

Inhibition of retrovirus infection Download PDF

Info

Publication number
OA10133A
OA10133A OA60622A OA60622A OA10133A OA 10133 A OA10133 A OA 10133A OA 60622 A OA60622 A OA 60622A OA 60622 A OA60622 A OA 60622A OA 10133 A OA10133 A OA 10133A
Authority
OA
OAPI
Prior art keywords
cys
pro
lys
gly
slpi
Prior art date
Application number
OA60622A
Other languages
English (en)
Inventor
Stephen Eisenberg
Sharon M Wahl
Robert C Thompson
Original Assignee
Amgen Boulder Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc, Us Health filed Critical Amgen Boulder Inc
Publication of OA10133A publication Critical patent/OA10133A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
OA60622A 1992-09-09 1995-03-09 Inhibition of retrovirus infection OA10133A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94336992A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
OA10133A true OA10133A (en) 1996-12-18

Family

ID=25479533

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60622A OA10133A (en) 1992-09-09 1995-03-09 Inhibition of retrovirus infection

Country Status (23)

Country Link
EP (1) EP0666755B1 (pt)
JP (2) JP3517238B2 (pt)
KR (1) KR100273620B1 (pt)
AT (1) ATE238062T1 (pt)
AU (1) AU681350B2 (pt)
CA (1) CA2141951C (pt)
CZ (1) CZ286953B6 (pt)
DE (1) DE69332904T2 (pt)
DK (1) DK0666755T3 (pt)
ES (1) ES2197153T3 (pt)
FI (1) FI951078A (pt)
HU (1) HU218892B (pt)
NO (1) NO315546B1 (pt)
NZ (1) NZ256246A (pt)
OA (1) OA10133A (pt)
PL (1) PL307864A1 (pt)
PT (1) PT666755E (pt)
RO (1) RO116164B1 (pt)
RU (1) RU2126266C1 (pt)
SG (1) SG48115A1 (pt)
SK (1) SK281127B6 (pt)
UA (1) UA41338C2 (pt)
WO (1) WO1994006454A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804930A1 (en) * 1994-03-23 1997-11-05 Tokyo Tanabe Company Limited Novel remedy for respiratory-tract viral disease
WO1997003694A1 (fr) * 1995-07-24 1997-02-06 Tokyo Tanabe Company Limited Remede contre les affections virales
ES2246498T3 (es) 1995-11-13 2006-02-16 Vitaleech Bioscience N.V. Aislados antivirales obtenidos de sanguijuelas.
US7276333B1 (en) 1999-05-13 2007-10-02 Japan Science And Technology Agency Viral infection inhibitor targeting integrase N-terminal domain
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
JP2804979B2 (ja) * 1988-11-28 1998-09-30 日本ケミカルリサーチ株式会社 エイズ治療および阻害剤
CA2007083A1 (en) * 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
JP2930713B2 (ja) * 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
DK0506769T3 (da) * 1989-12-18 1994-11-28 Transgene Sa Farmaceutisk præparat til behandling eller forebyggelse af retrovirus-infektioner
GR1001044B (el) * 1991-06-03 1993-04-28 Logothetou Rella Eleni Μηχανισμός διή?ησης νεοπλασματικών κυττάρων και η χρήση του αναστολέα της Ca2+ -εξαρτώμενης ουδέτερης πρωτεάσης για την παρασκευή φαρμακευτικών αντικαρκινικών συν?έσεων.

Also Published As

Publication number Publication date
FI951078A0 (fi) 1995-03-08
CZ286953B6 (en) 2000-08-16
CA2141951A1 (en) 1994-03-31
AU681350B2 (en) 1997-08-28
JP2004002455A (ja) 2004-01-08
UA41338C2 (uk) 2001-09-17
HUT75126A (en) 1997-04-28
KR100273620B1 (ko) 2000-12-15
PT666755E (pt) 2003-09-30
JP3517238B2 (ja) 2004-04-12
AU4853093A (en) 1994-04-12
ES2197153T3 (es) 2004-01-01
SK281127B6 (sk) 2000-12-11
JPH08505042A (ja) 1996-06-04
KR950703357A (ko) 1995-09-20
RU95109909A (ru) 1997-03-27
EP0666755B1 (en) 2003-04-23
CA2141951C (en) 2007-04-24
CZ55995A3 (en) 1996-01-17
SK29795A3 (en) 1997-02-05
FI951078A (fi) 1995-03-08
EP0666755A1 (en) 1995-08-16
HU9500682D0 (en) 1995-04-28
NO315546B1 (no) 2003-09-22
WO1994006454A2 (en) 1994-03-31
HU218892B (hu) 2000-12-28
DK0666755T3 (da) 2003-08-04
RO116164B1 (ro) 2000-11-30
DE69332904T2 (de) 2003-11-06
RU2126266C1 (ru) 1999-02-20
PL307864A1 (en) 1995-06-26
NZ256246A (en) 1997-08-22
WO1994006454A3 (en) 1994-08-18
SG48115A1 (en) 1998-04-17
NO950897L (no) 1995-03-08
ATE238062T1 (de) 2003-05-15
DE69332904D1 (de) 2003-05-28
NO950897D0 (no) 1995-03-08

Similar Documents

Publication Publication Date Title
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
JP2656938B2 (ja) dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物
JPH11507632A (ja) 併用療法を用いたhivおよび他のウイルス感染の治療
KR19990082084A (ko) 인터페론으로 선행치료한 hcv 환자를 재치료하기 위한 제약학적 조성물
WO1995017899A2 (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US6017880A (en) Inhibition of retrovirus infection
OA10133A (en) Inhibition of retrovirus infection
JPH07267874A (ja) Hiv感染に対する組合せ化学療法
US6869925B1 (en) Inhibition of retrovirus infection
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
KR20050057329A (ko) HIV gp41-유래된 펩티드의 향상된 투여를 위한제약학적 조성물 및 이의 치료적 용도
EP0960886A1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
JPH10251159A (ja) Il−6を含む血清尿酸値低下剤
EP1497323B1 (en) Multiple branch peptide constructions comprising from 2 to 16 branches of the peptide rqgys or from 8 to 16 branches of the peptide rqgy providing from the hiv gp41 glycoprotein
JPWO2008050830A1 (ja) 抗hiv剤
AU763289C (en) Use of GM-CSF to inhibit development of drug resistance in HIV+ patients
WO2000045833A1 (en) Hiv drug resistance system
Pomerantz et al. Therapy of human immunodeficiency virus infections
WO1995023610A1 (en) Pharmaceutical composition containing thymoctonan and azt
HU203971B (en) Process for producing synergetic combination pharmaceutical compositions comprising 3'-azido-3'-deoxythymidine and one more active ingredient